 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- SZN-1326 / Surrozen
SZN-1326, A WNT MIMETIC, DECREASED INTESTINAL FIBROSIS IN A DEXTRAN SULFATE SODIUM (DSS)-INDUCED CHRONIC COLITIS MOUSE MODEL (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_1199;
Conclusion : In a chronic mouse colitis model, SZN-1326 at various dosing regimens improved intestinal epithelial repair, and decreased colitis-associated collagen deposition. In contrast, anti-TNFa antibody treatment slightly decreased collagen deposition without any improvement in colon histology in this model.
- | SZN-1326 / Surrozen
Journal: Robust colonic epithelial regeneration and amelioration of colitis via FZD-specific activation of Wnt signaling. (Pubmed Central) - Jul 27, 2022
In contrast, anti-TNFa antibody treatment slightly decreased collagen deposition without any improvement in colon histology in this model. It is feasible to design Wnt mimetics such as SZN-1326-p that impact damaged intestine epithelium specifically and restore its physiological functions, an approach that holds promise for treating epithelial damage in inflammatory bowel disease.
- SZN-1326 / Surrozen
SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES (Science Lounge) - Jul 20, 2022 - Abstract #UEGW2022UEGW_1917;
The minimal, non-adverse, clinical pathology findings in rats were not correlated with any macro- or microscopic histopathological changes. Thus, the NOAEL is the highest IV administered dosage of 75mg/kg/dose with no SZN-1326 related adversity observed at 30 mg/kg dosed SC.
- SZN-1326 / Surrozen
SZN-1326, A WNT MIMETIC, IMPROVED EPITHELIAL HEALING AND DECREASED COLLAGEN DEPOSITION IN A DEXTRAN SULFATE SODIUM-INDUCED COLITIS MOUSE MODEL (Lehar 4) - Jul 20, 2022 - Abstract #UEGW2022UEGW_1103;
Thus, the NOAEL is the highest IV administered dosage of 75mg/kg/dose with no SZN-1326 related adversity observed at 30 mg/kg dosed SC. In an acute mouse IBD model, SZN-1326 treatment, in a dose-dependent manner, induced mucosal healing and restored the epithelial barrier resulting in reduced inflammation, reduced colitis‐associated collagen deposition, improved body weight, and reduced disease activity.
- ||| SZN-1326 / Surrozen
$SRZN Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis https://t.co/E0ZtFJpsZn (Twitter) - May 16, 2022
- SZN-1326 / Surrozen
SZN-1326 PROMOTES COLONIC MUCOSAL HEALING IN AN ACUTE INJURY MODEL OF IBD BY FIRST ACCELERATING EPITHELIAL REGENERATION AND SECONDARILY REDUCING INFLAMMATION (24 - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_2681;
Conclusion : In this acute damage context, SZN-1326 promoted mucosal healing by transiently inducing epithelial progenitor cell expansion and accelerating epithelial repair. Secondary to its initial impact on the epithelium, SZN-1326 reduced stromal and immune cytokine signaling and immune cell infiltration.
- | SZN-1326 / Surrozen
New P1 trial: A Phase 1/1b, Three-Part, Randomised, Placebo-Controlled, Single- and Multiple-Ascending-Dose Studyto Evaluate the Safety, Pharmacokinetics, and Activity of SZN-1326 in Healthy Volunteers and in Subjects with Moderate to Severe Ulcerative Colitis (EUDRACT) - Apr 1, 2022
P1, N=68, Not yet recruiting, Sponsor: Surrozen Operating, Inc.
- | SZN-1326 / Surrozen
New P1 trial: A Phase 1/1b, Three-Part, Randomised, Placebo-Controlled, Single- and Multiple-Ascending-Dose Studyto Evaluate the Safety, Pharmacokinetics, and Activity of SZN-1326 in Healthy Volunteers and in Subjects with Moderate to Severe Ulcerative Colitis (EUDRACT) - Feb 26, 2022
P1, N=68, Not yet recruiting, Sponsor: Surrozen Operating, Inc.
- SZN-1326 / Surrozen
SZN-1326 promotes colonic mucosal healing in an acute injury model of IBD by first accelerating epithelial regeneration and secondarily reducing inflammation (Virtual Poster exhibition) - Dec 29, 2021 - Abstract #ECCOIBD2022ECCO_IBD_793;
Conclusion In this acute damage context, SZN-1326 promoted mucosal healing by transiently inducing epithelial progenitor cell expansion and accelerating epithelial repair. Secondary to its initial impact on the epithelium, SZN-1326 reduced stromal and immune cytokine signaling and immune cell infiltration.
- SZN-1326 / Surrozen
[VIRTUAL] PHARMACOKINETIC AND NONCLINICAL SAFETY EVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, IN NON-HUMAN PRIMATES (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4564;
Secondary to its initial impact on the epithelium, SZN-1326 reduced stromal and immune cytokine signaling and immune cell infiltration. The data from these studies indicate that SZN-1326 can be safety administered to NHPs, with PK suitable for use in humans, and support further investigation of this molecule in the setting of epithelial regeneration and mucosal healing in IBD.
- SZN-1326 / Surrozen
[VIRTUAL] SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORING EPITHELIAL INTEGRITY AND MITIGATING COLITIS IN A CHRONIC DSS MODEL (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4331;
Anti-IL12/23p40 antibody at 10 mg/kg given 8 times starting on Day 7 improved colon histology and reduced serum levels of IL-6 but had no effect on DAI. Treatment with anti-TNF-a antibody led only to serum lipocalin-2 reduction without any effects on DAI or colon histology.
- SZN-1326 / Surrozen
[VIRTUAL] PHARMACOKINETIC AND NONCLINICAL SAFETY EVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, IN NON-HUMAN PRIMATES (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2384;
Treatment with anti-TNF-a antibody led only to serum lipocalin-2 reduction without any effects on DAI or colon histology. The data from these studies indicate that SZN-1326 can be safety administered to NHPs, with PK suitable for use in humans, and support further investigation of this molecule in the setting of epithelial regeneration and mucosal healing in IBD.
- SZN-1326 / Surrozen
[VIRTUAL] SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORING EPITHELIAL INTEGRITY AND MITIGATING COLITIS IN A CHRONIC DSS MODEL (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2151;
Anti-IL12/23p40 antibody at 10 mg/kg given 8 times starting on Day 7 improved colon histology and reduced serum levels of IL-6 but had no effect on DAI. Treatment with anti-TNF-a antibody led only to serum lipocalin-2 reduction without any effects on DAI or colon histology.
- SZN-1326 / Surrozen
[VIRTUAL] SZN-1326 PROMOTES COLONIC MUCOSAL HEALING IN AN ACUTE INJURY MODEL OF IBD BY EXPANDING THE PROGENITOR POOL AND ACCELERATING DIFFERENTIATION: Discussion (Hall 2) - Jul 20, 2021 - Abstract #UEGW2021UEGW_1562;
- SZN-1326 / Surrozen
[VIRTUAL] SZN-1326 PROMOTES COLONIC MUCOSAL HEALING IN AN ACUTE INJURY MODEL OF IBD BY EXPANDING THE PROGENITOR POOL AND ACCELERATING DIFFERENTIATION (Hall 2) - Jul 20, 2021 - Abstract #UEGW2021UEGW_1561;
Treatment with anti-TNF-a antibody led only to serum lipocalin-2 reduction without any effects on DAI or colon histology. The key mechanism underlying the ability of SZN-1326 to promote mucosal healing is its ability to induce stem and progenitor cell expansion that ultimately accelerates epithelial repair and secondarily reduces inflammation.
- SZN-1326 / Surrozen
[VIRTUAL] SZN-1326, A WNT SIGNAL ACTIVATOR, IS MORE EFFICACIOUS THAN CYCLOSPORINE A IN AN ACUTE DSS MODEL: Discussion (Hall 2) - Jul 20, 2021 - Abstract #UEGW2021UEGW_1560;
- SZN-1326 / Surrozen
[VIRTUAL] SZN-1326, A WNT SIGNAL ACTIVATOR, IS MORE EFFICACIOUS THAN CYCLOSPORINE A IN AN ACUTE DSS MODEL (Hall 2) - Jul 20, 2021 - Abstract #UEGW2021UEGW_1559;
In an acute mouse IBD model, SZN-1326, at various dosing regimens, stimulated intestinal epithelial regeneration, induced mucosal healing and restored the epithelial barrier resulting in reduced inflammation, improved body weight and reduced disease activity. In contrast, Cyclosporine A only mildly reduced disease activity and Lipocalin-2 levels.
- SZN-1326 / Surrozen
[VIRTUAL] PHARMACOKINETIC AND NONCLINICAL SAFETY EVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, IN NON-HUMAN PRIMATES (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_553;
In contrast, Cyclosporine A only mildly reduced disease activity and Lipocalin-2 levels. The data from these studies indicate that SZN-1326 can be safety administered to NHPs, with PK suitable for use in humans, and support further investigation of this molecule in the setting of epithelial regeneration and mucosal healing in IBD.
- SZN-1326 / Surrozen
[VIRTUAL] SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORING EPITHELIAL INTEGRITY AND MITIGATING COLITIS IN A CHRONIC DSS MODEL (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_320;
Anti-IL12/23p40 antibody at 10 mg/kg given 8 times starting on Day 7 improved colon histology and reduced serum levels of IL-6 but had no effect on DAI. Treatment with anti-TNF-a antibody led only to serum lipocalin-2 reduction without any effects on DAI or colon histology.
- SZN-1326 / Surrozen
[VIRTUAL] SZN-1326, a Wnt agonist, improved epithelial healing and ameliorated colitis in a chronic DSS model, in stark contrast to anti-TNF and anti-IL-12/23p40 antibodies (Virtual Poster Exhibition) - May 5, 2021 - Abstract #ECCOIBD2021ECCO_IBD_864;
Conclusion In a chronic mouse IBD model, SZN-1326 at various dosing regimens stimulated intestinal epithelial regeneration, induced mucosal healing and restored the epithelial barrier resulting in reduced inflammation, improved body weight and reduced disease activity. In contrast, treatment with anti-TNFα or anti-IL-12/23p40 antibodies led to reduction only in certain serum inflammatory cytokines but had no efficacy on DAI or colon histology in this model.
- SZN-1326 / Surrozen
[VIRTUAL] SZN-1326, a Wnt signal activator, is more efficacious than cyclosporine A in an acute DSS model (Virtual Poster Exhibition) - May 5, 2021 - Abstract #ECCOIBD2021ECCO_IBD_832;
Conclusion In an acute mouse IBD model, SZN-1326 at various dosing regimen stimulated intestinal epithelial regeneration, induced mucosal healing and restored the epithelial barrier resulting in reduced inflammation, improved body weight and reduced disease activity. In contrast, Cyclosporine A showed only a mild effect on reducing DAI and lipocalin-2.
- SZN-1326 / Surrozen
[VIRTUAL] SZN-1326 PROMOTES COLONIC MUCOSAL HEALING IN AN ACUTE INJURY MODEL OF IBD BY EXPANDING THE PROGENITOR POOL AND ACCELERATING DIFFERENTIATION (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_3521;
Consistent with mucosal healing, there was a decrease in the number of inflammatory cells and signals (e.g., S100a8, S100a9) in SZN-1326-treated colon relative to control samples in the acute DSS model. In sum, the key mechanism underlying the ability of SZN-1326 to promote mucosal healing is its ability to induce stem and progenitor cell expansion that ultimately accelerates epithelial repair and secondarily reduces inflammation.
- SZN-1326 / Surrozen
[VIRTUAL] SZN-1326, A WNT SIGNAL ACTIVATOR, IMPROVED EPITHELIAL HEALING AND AMELIORATED COLITIS IN AN ACUTE DSS MODEL (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_1006;
In sum, the key mechanism underlying the ability of SZN-1326 to promote mucosal healing is its ability to induce stem and progenitor cell expansion that ultimately accelerates epithelial repair and secondarily reduces inflammation. Treatment with SZN-1326 stimulated intestinal epithelial regeneration, induced mucosal healing and restored the epithelial barrier resulting in reduced inflammation, improved body weight and reduced disease activity in an acute DSS model.